Skip to content

Advertisement

  • Research
  • Open Access

Population-based statistical inference for temporal sequence of somatic mutations in cancer genomes

BMC Medical Genomics201811 (Suppl 2) :29

https://doi.org/10.1186/s12920-018-0352-z

  • Published:

Abstract

Background

It is well recognized that accumulation of somatic mutations in cancer genomes plays a role in carcinogenesis; however, the temporal sequence and evolutionary relationship of somatic mutations remain largely unknown.

Methods

In this study, we built a population-based statistical framework to infer the temporal sequence of acquisition of somatic mutations. Using the model, we analyzed the mutation profiles of 1954 tumor specimens across eight tumor types.

Results

As a result, we identified tumor type-specific directed networks composed of 2-15 cancer-related genes (nodes) and their mutational orders (edges). The most common ancestors identified in pairwise comparison of somatic mutations were TP53 mutations in breast, head/neck, and lung cancers. The known relationship of KRAS to TP53 mutations in colorectal cancers was identified, as well as potential ancestors of TP53 mutation such as NOTCH1, EGFR, and PTEN mutations in head/neck, lung and endometrial cancers, respectively. We also identified apoptosis-related genes enriched with ancestor mutations in lung cancers and a relationship between APC hotspot mutations and TP53 mutations in colorectal cancers.

Conclusion

While evolutionary analysis of cancers has focused on clonal versus subclonal mutations identified in individual genomes, our analysis aims to further discriminate ancestor versus descendant mutations in population-scale mutation profiles that may help select cancer drivers with clinical relevance.

Keywords

  • Somatic mutation
  • Cancer genome
  • Mutation accumulation

Background

Various types of genomic aberrations accumulate in cancer genomes and play roles in the development and progression of the disease [1]. It has long been recognized that cancer genomes undergo a stepwise progression in which they acquire somatic mutations in a sequential order during their evolution. This model is relatively well established in colorectal cancer genomes [2], and may be true for other types of cancer. Recent advances in high-throughput sequencing technologies have enabled screening of cancer genomes for well-known cancer-related genomic aberrations such as somatic mutations, DNA copy number alterations, and chromosomal translocations [3]. Genomic snapshots of human solid tumors can only be obtained by surgical intervention and such procedures have limitations for a full understanding of the temporal or longitudinal evolution of individual cancer genomes. While current cancer genome studies are mainly focused on the identification of significant recurrent genomic aberrations as potential cancer drivers, the inference of acquisition order of somatic mutations may provide mechanistic insights into the evolution of the cancer genome and have potential clinical relevance.

Several studies have been proposed to investigate the order of acquisition of genomic alterations. For example, Attolini et al. proposed a mathematical approach to determine the sequential order of APC, KRAS, and TP53 mutations in 70 colorectal cancer samples [4]. They estimated the mutation rate per allele and predicted the temporal sequences for mutations acquired in these genes. Hu et al. tried to identify tumor driver genes using association rule mining [5]. In addition, some researchers tried to estimate the tumor initiation time. Tomasetti et al. modeled the process of mutation accumulation and verified that a substantial number of somatic mutations may have appeared before the onset of neoplasia [6]. Also, Foo et al. investigated driver mutations in the evolutionary processes of mutation accumulation using healthy and tumor tissues [7]. However, most of these previous reports used binary genomic data (e.g., calls for presence or absence of mutations or copy number alterations) and did not exploit information regarding the clonality of mutations (e.g., clonal vs. subclonal mutations).

Here, we inferred the acquisition order of somatic mutations (hereafter in this study, we define somatic mutations as non-silent single nucleotide variations [SNVs] including missense, nonsense, and splice site mutations) based on information of the cancer cell fraction (CCF) measured for each mutation, using 1954 tumor specimens from eight major tumor types of the Cancer Genome Atlas (TCGA) consortium: 90 samples from bladder urothelial carcinoma (BLCA); 733 from breast invasive carcinoma (BRCA); 246 from colorectal adenocarcinoma (COADREAD); 265 from head and neck squamous cell carcinoma (HNSC); 42 from kidney renal clear cell carcinoma (KIRC); 290 from lung adenocarcinoma (KIRC); 118 from lung squamous cell carcinoma (LUSC); and 170 from uterine corpus endometrial carcinoma (UCEC). The CCFs, as variant allele frequencies (VAFs) adjusted for the tumor purity and global/local ploidy, are a measure of the clonality of given somatic mutations. CCFs have been used to distinguish clonal or subclonal mutations in individual cancer genomes [8]. In theory, clonal mutations represent early genomic events that have occurred in a founder cell and are maintained during the clonal proliferation whereas subclonal mutations represent late genomic events that are not yet fixed by clonal amplification or clonal sweeps. Under the infinite sites model of genome evolution with no homoplasy, somatic mutations with lower CCFs cannot occur earlier than those with higher CCFs [9]. Although a recent study showed that the mutation acquisition order affects cancer and cancer therapy [10], it is still largely unclear how to aggregate the information on individual genomes such as the CCFs to facilitate population-scale inference of temporal ordering of somatic mutations. In this study, we established a statistical model to infer the temporal order of somatic mutations observed across multiple cancer genomes and applied the method to a pan-cancer landscape of somatic mutations of eight major tumor types.

Methods

Study dataset

All experiments were carried out using publicly available TCGA pan-cancer data for eight tumor types, BLCA, BRCA, COADREAD, HNSC, KIRC, LUAD, LUSC, and UCEC. All mutation data were obtained from mutation annotation format (MAF) files with available sequencing read abundance of mutant and wildtype alleles to calculate VAFs. Among these somatic mutations, only the non-silent mutations (nonsense, mutation, and splice site SNVs) were extracted. We further selected mutations with minimum number of variant alleles ≥ 5 and minimum number of total alleles ≥ 30. The integer-level copy number, tumor ploidy and purity values estimated by ABSOLUTE [11] were downloaded from the Synapse website for TCGA pancancer analysis (https://www.synapse.org/\#!Synapse:syn1703335) and used for the estimation of CCFs.

Estimating cancer cell fraction

The CCF is defined as the proportion of cancer cells harboring the mutations for each variant, and can be estimated using a method outlined by Landau et al. [12]. Briefly, for a single point mutation mi at a sample n, \(P\left (C^{n}_{i}\right)\), the posterior distribution for the CCF \(C^{n}_{i}\) is obtained from binomial distribution of the observed VAF over the expected VAFs calculated using a uniform grid of 100 CCF values (\(C^{n}_{i} \in \) [0.01, 1]), and subsequently normalized. Then, the probability mass function of the \(P\left (C^{n}_{i}\right)\) is represented as:
$$ P\left(C^{n}_{i}\right) = \sum\limits^{1}_{k=0.01} P\left(C^{n}_{i}=k\right) $$
(1)

Statistical inference of mutational temporal order of somatic mutations

The mutational order for a pair of somatic mutation, mi and mj, was determined using a generalized likelihood ratio test (GLRT). This examines whether the occurrence of somatic mutation mi precedes that of another somatic mutation mj. Then, a null hypothesis H0 and an alternative hypothesis H1 follow:
$$H_{0}: m_{i}~\text{is an ancestor of}~ m_{j} (m_{i} \to m_{j}) $$
$$H_{1}: m_{i}~\text{is not an ancestor of}~ m_{j} $$
Suppose that there are a total of N samples, which have somatic mutations both in mi and mj. The CCF for mi and mj is represented as a set of independent and identically distributed (i.i.d.) variables, as \(C_{i}=\left ({C}^{1}_{i},\ C^{2}_{i},\ \dots,\ C^{N}_{i}\right)\) and \(C_{j}=\left ({C}^{1}_{j},\ C^{2}_{j},\ \dots,\ C^{N}_{j}\right)\), respectively. In the n-th sample among the total N, the evolutionary precedence of the two mutations, mi and mj, was approximated from the comparison of their CCFs, \(C^{n}_{i}\) and \(C^{n}_{j}\), respectively. That is, \(C^{n}_{i} \geq C^{n}_{j}\) implies that mutation m i is an ancestor of the mutation mj in the sample n. Suppose that a random variable \(D^{n}_{ij}\) represents the difference of two variables, \(C^{n}_{i}\) and \(C^{n}_{j}\), and \(\hat {C^{n}_{i}}=P\left (C^{n}_{i}\right)\) and \(\hat {C^{n}_{j}}=P\left (C^{n}_{j}\right)\) are the estimated distribution of the CCFs at a mutation mi and mj, respectively, in the sample n. Then the two hypotheses can be re-written as follows:
$$\mathrm{H}_{0}: \hat{D^{n}_{ij}}\geq\thinspace0 $$
$$\mathrm{H}_{1}: \hat{D^{n}_{ij}}<\thinspace0 \,, $$
where \(\hat {D^{n}_{ij}}\ \)is the estimated distribution of Dij at the sample n. By the definition of GLRT under i.i.d. condition, the statistics are represented as:
$$\begin{array}{@{}rcl@{}} \Lambda &=& \frac{max_{H_{0}}L\left(\hat{D^{1}_{ij}}, \hat{D^{2}_{ij}},..., \hat{D^{N}_{ij}}\right) }{max_{{H_{0}}\cup{H_{1}}}L\left(\hat{D^{1}_{ij}}, \hat{D^{2}_{ij}},..., \hat{D^{N}_ {ij}}\right)} \\ &=& \prod\limits_{n=1}^{N} \frac{max_{H_{0}}L\left(\hat{D^{n}_{ij}} | {D^{n}_{ij}} \in [0,+\infty]\right)}{max_{{H_{0}}\cup{H_{1}}}L\left(\hat{D^{n}_{ij}} | {D^{n}_{ij}} \in [-\infty,+\infty]\right)}\,, \end{array} $$
(2)
where L(·) is a likelihood function. Using the characteristics of the convolution of two independent random variables, the probability mass function of the variable \(D^{n}_{ij} \left (D^{n}_{ij} = C^{n}_{i} - C^{n}_{j}\right)\) is expressed as
$$ P(D^{n}_{ij}=z)=\sum\limits^{1}_{k=0}{P\left(C^{n}_{i}=k\right)P\left(C^{n}_{j}=-z+k\right)} $$
(3)
Then, Eq. 2 is rewritten with the property of Eq. 3 as follows:
$$ \Lambda = \prod\limits_{n=1}^{N} \frac{max_{H_{0}}\sum_{z=0}^{+\infty}P\left(\hat{D^{n}_{ij}}=z)\right)}{max_{{H_{0}}\cup{H_{1}}}\sum_{-\infty}^{+\infty}P\left(\hat{D^{n}_{ij}}=z)\right)} $$
(4)
Equation 4 with k [0.01, 1] is rewritten as
$$ \Lambda = \prod\limits_{n=1}^{N} \frac{max_{H_{0}}\sum_{z=0}^{1}P\left(\hat{D^{n}_{ij}}=z)\right)}{max_{{H_{0}}\cup{H_{1}}}\sum_{-1}^{1}P\left(\hat{D^{n}_{ij}}=z)\right)} $$
(5)
For the convenience of the calculation, the statistics of Eq. 5 are changed to a logarithmic value:
$$\begin{array}{@{}rcl@{}} log(\Lambda)_{I_{D_{max}<0}} \!\!&\!=&\!\!\sum\limits_{n=1}^{N}log\left(\frac{max_{H_{0}}\sum_{z=0}^{1}P\left(\hat{D^{n}_{ij}}=1\right)}{max_{{H_{0}}\cup{H_{1}}}\sum_{z=-1}^{1}P\left(\hat{D^{n}_{ij}}=1\right)}\right){I_{\hat{{D_{ij}^{n}}_{max}}<0}} \\ \!\!&=& \!\!\sum\limits_{n=1}^{N}\left(log\left(max_{H_{0}}\sum_{z=0}^{1}P\left(\hat{D^{n}_{ij}}=1\right)\right)\right. \\ \!\!&& \left. \! \!- log\left(max_{{H_{0}}\cup{H_{1}}}\!\!\sum_{z=-1}^{1}\!\!P\left(\hat{D^{n}_{ij}}\,=\,1\right)\right)\right){I_{\hat{{D_{ij}^{n}}_{max}}<0}} \end{array} $$
(6)

\(I_{{{\hat {D^{n}_{ij}}}_{max}}<0}\) is an indicator function for whether the maximum value of the likelihood function for \(\hat {D^{n}_{ij}}\) is observed at z < 0. \(I_{{{\hat {D^{n}_{ij}}}_{max}}<0} = 0\) means that the numerator and denominator values are identical. The null hypothesis(H0) is not rejected if the log(Λ) is significantly large.

The statistical tests were carried out using mutant gene pairs with number of cases > 10. The statistical cutoff for the log(Λ) was obtained by random re-arrangement of the original data to generate a background distribution of the GLRT statistics. The cutoff was determined as a 5th percentile value from the background distribution of the 100,000 randomized experiments.

Results

Co-occurring pairs of somatic mutations

We first examined genes with frequent mutations and their co-occurrence patterns using mutation profiles of 1954 patients across eight TCGA tumor types (BLCA, BRCA, COADREAD, HNSC, KIRC, LUAD, LUSC, and UCEC). A mean number of 120 somatic mutations (nonsilent SNVs; missense, nonsense and splice site mutations) were observed (1 to 1597 mutations per case; median of 59 mutations; Table 1). Figure 1(a) shows the distribution of somatic mutations for 10 genes with the most frequent somatic mutations across all cases examined. To investigate gene pairs, we employed a scoring system of mutation co-occurrence. The score of the co-occurrence, SCORE-CO is calculated by summing the outputs of the logical conjunction (’AND’ gate) for the binary input data as the presence or absence of the somatic mutations in the given pair of two genes and by dividing the value by the number of total cases in the dataset. Table S1 shows the co-occurring pairs of somatic mutations observed in no fewer than 10 cases per tumor type (Additional file 1: Table S1). The gene pairs with high SCORE-CO include TTN and MUC16 whose frequent mutations are largely due to their large gene size (36,800 and 14,500 amino acids, respectively) rather than their functional significance. Thus, we focused on mutations in known cancer-related genes or the Cancer Gene Census (CGC) [13] (Fig. 1(b)). The co-occurring mutation gene pairs with high SCORE-CO were tumor type-specific, e.g., gene pairs of TP53 and PIK3CA were highly ranked in BLCA, BRCA, COADREAD, HNSC, LUSC, UCEC (SCORE-CO = 0.089 for 8 cases with the co-occurrence / total 90 patients, 0.055 for 40 cases, 0.085 for 21 cases, 0.083 for 22 cases, 0.085 for 10 cases, 0.106 for 18 cases, respectively) and to a lesser extent in LUAD (SCORE-CO =0.024 for 7 cases). However, the pair of TP53 and PIK3CA was not identified in KIRC. LRP1B mutants frequently co-occurred with TP53 mutants in HNSC, LUAD and LUSC. APC mutants were frequently observed with TP53 or KRAS mutations in COADREAD. In addition, some of the mutation occurrences were tumor type-specific, e.g., PIK3CA mutations showed co-occurrence with FAT4 mutations with a high frequency in BLCA, but mainly co-occurred with PTEN mutations in UCEC.
Fig. 1
Fig. 1

Frequent somatic mutations and co-occurring mutation pairs. a Distribution of somatic mutations observed in all cases examined. The plot is shown for the top 10 frequently mutated genes across all cases. A tumor patient with a somatic mutation is marked as gray in each column. b Frequently observed gene pairs of somatic mutations are shown for each tumor type. The heatmaps of SCORE-CO are shown for the top 7 genes among CGC in a given tumor type. The color indicator of SCORE-CO is shown separately (right)

Table 1

Number of non-silent mutations in each tumor type

 

Nonsense

Missense

Splice site

 

mutation

mutation

mutation

BLCA

1430

14,685

560

BRCA

2512

30,499

815

COADREAD

2348

37,702

765

HNSC

2110

26,040

1179

KIRC

185

2592

513

LUAD

4310

53,898

3090

LUSC

2004

23,485

640

UCEC

1790

21,327

538

Temporal sequence of mutations in cancer-related genes

To infer the temporal sequence of the somatic mutations in cancer-related genes, we first distinguished two types of mutations, clonal and subclonal mutations, based on CCF. The distinction was made by a criterion proposed by Landau et al. [12], and the measure of CCF was clearly higher for the clonal mutations than for subclonal mutations (P value <1.010−20).

Based on the CCF, we established a statistical framework for the population-based inference of temporal order between somatic mutations in a gene pair and applied the method for the mutation profiles from individual tumor types. Using the results from permutation tests to determine the minimum case number to identify the statistically significant mutation pairs with sequential orders (i.e., log(Λ)≈ 0 at the 5th percentile of the 100,000 re-sampling experiments at the small number of cases), we performed the test for all pairs of somatic mutations observed in no fewer than 10 cases (Additional file 2: Figure S1 (a)). Additional file 2: Figure S1 (b) shows the distribution of the number of the mutation pairs in each tumor type. The ancestor-descendant relationship in a mutation pair was then inferred by GLRT statistics and the significance was estimated for each direction. Figure 2 shows the mutation orders of cancer-related genes for six tumor types except for BLCA and KIRC, which did not have any significant mutant pairs within cancer-related genes (P value cutoff was 0.05).
Fig. 2
Fig. 2

Tumor type-specific networks representing the mutation order among cancer-related genes. The thickness of the edges is proportional to the −logP value and the size of the nodes corresponds to the proportion of the genes with somatic mutations

The mutation order of gene pairs was largely distinct across tumor types, suggesting that the accumulation patterns or hierarchy of somatic mutations are lineage-dependent. However, some of the mutation pairs and their orders were consistently observed across tumor types. For example, a frequently co-occurred mutation pair of TP53 and LRP1B (Fig. 1(b)) was observed as ancestor (TP53) - descendant (LRP1B) pairs (TP53LRP1B) in COADREAD, HNSC, LUAD, and LUSC, with statistical significance (P value =3.010−5, 0.00044, 0.00029 and 0.00058, respectively). In addition, KMT2C mutation was consistently observed as a descendant of TP53 mutations (TP53KMT2C) in HNSC and LUAD (P value =3.010−5 and 5.010−5, respectively).

When we investigated mutation pairs in each tumor type, three ordered pairs were identified with statistical significance in BRCA (P value < 0.05) (Fig. 2). The hierarchy of the three genes (TP53PIK3CACDH1) in BRCA suggests that TP53 mutations represent early events that are followed by subsequent PIK3CA mutations (P value =0.034), then CDH1 mutations (P value =3.010−5). This mutation sequence can be functionally interpreted as follows: genomic integrity is disrupted with TP53 mutations followed by cancer cell proliferation stimulated by PIK3CA mutations and the acquisition of later invasive/metastatic potential with CDH1 mutations. This mutation order between TP53 and PIK3CA was also found in HNSC (P value =3.010−5), suggesting that the TP53PIK3CA axis may play important roles in the development of epithelial tumors. NCOR1 mutation was also observed as an ancestor for PIK3CA mutation (P value =0.00036) and it has been reported that functional inactivation of NCOR1 as a HDAC3 cofactor may produce genomic instability, which is functionally equivalent to the loss of TP53 [14].

For LUAD, 16 ordered pairs were identified with statistical significance. The elevated mutation abundance (mean of 211 mutations per LUAD case vs. mean of 120 mutations for total cases) and the relatively large size of the cohort (290 cases) may explain this number, but only one mutation pair was observed in LUSC with similar mutation abundance (average 221 mutations per cases) and a smaller number of cohorts (118 cases). TP53 mutation appeared as a hub in the 16 edge-based network of LUAD and was identified as ancestor in most mutation pairs. TP53 mutations have been implicated in tumor development and progression across many tumor types [1517]. Our analysis also suggests that EGFR mutations may be earlier genomic events among the mutations in the LUAD pathogenesis [18]. A substantial fraction of EGFR mutations in LUAD are considered to be early addicted targets of targeted therapy [19, 20], suggesting that they represent early genomic aberrations together with TP53 mutations. In the case of LUSC, the TP53LRP1B ordered mutation pair was solely observed.

In HNSC, NOTCH1 mutations may be earlier events than TP53 mutations. Although it is mutated at a lower frequency than TP53 in HNSC, NOTCH1 has been highlighted as a potential cancer driver and tumor suppressor in HNSC [21].

For COADREAD, ordered pairs of somatic mutations involving APC, KRAS and TP53 are observed and have been recognized to have pivotal roles associated with colorectal carcinogenesis [2]. Colorectal carcinogenesis is one of the well-established stepwise cancer progression models and involves sequential acquisition of APC, KRAS, and TP53 mutations at colorectal dysplasia, adenoma, and carcinoma stages, respectively [22, 23]. Our inferred hierarchy from somatic mutations suggested that KRAS mutations were the earliest events in colorectal carcinogenesis. Given that our statistical model only considered the SNV, tumor suppressors that can be inactivated by chromosomal deletions, such as APC, may not be adequately assessed for order of mutation.

Accumulation of somatic mutations including non-CGC gene

We next performed analysis beyond the known cancer-related genes (Additional file 3: Table S2). For individual genes, we calculated SCORE-AN by subtracting the number of genes marked as a descendant from the number of genes marked as an ancestor in a given tumor type. SCORE-AN for the genes is provided in Additional file 4: Table S3 and Fig. 3. A large positive value of the SCORE-AN means that the corresponding gene is more likely to be an ancestor or early clonal event and can be regarded as a potential driver of the corresponding tumor type. In contrast, the genes with a large negative value would be passengers or late mutation events.
Fig. 3
Fig. 3

Ancestral scores of genes in each tumor type. The figure shows SCORE-AN (y-axis), calculated as the number of the ancestors minus the number of descendants for each gene. Genes are sorted in descending order of the SCORE-AN for each tumor type (x-axis). For LUAD, genes with absolute number of SCORE-AN > 10 are plotted, and for LUSC genes with absolute number of SCORE-AN > 2 are shown

Consistent with our assumption, many of the genes with high SCORE-AN values or genes with more calls for ancestors were cancer-related genes listed in CGC (Fig. 3). For example, the genes with a positive SCORE-AN were TP53 and KMT2D in BLCA and TP53, PIK3CA and NCOR1 in BRCA. However, the two longest genes in the human genome, TTN and MUC16, which are likely to be passengers without putative roles generally showed negative values of SCORE-AN even though these two genes showed frequent mutations as shown in Fig. 1(a). In the case of UCEC, TTN and TP53 showed a positive and negative value, respectively. For this tumor type, TP53 mutation was marked as a descendant for PIK3CA and PTEN mutations. It was also noted that TP53 mutations were also observed as descendants of KRAS mutations in COADREAD. For theses tumor types (UCEC and COADREAD), an unusual tendency for elevated mutation rates was observed and this might be responsible for the unique evolutionary position of TP53 [24].

To further evaluate the potential functional significance of the SCORE-AN, we carried out Gene Set Enrichment Analysis (GSEA) [25] to identify the functional gene sets significantly enriched for genes with high or low SCORE-AN. Additional file 5: Table S4, Additional file 6: Table S5, Additional file 7: Table S6, and Additional file 8: Table S7 show the GSEA results only for LUAD, in which there was a high enough number of the ranked genes (427 genes) for analysis. The results for positively ranked genes on C5bp predefined gene sets (gene ontology, biological process in MSigDB), showed that most of the enriched gene sets were related to cell cycle and cellular transport (Additional file 5: Table S4). For gene sets enriched with low SCORE-AN, the significantly enriched genes were related to epidermal or epithelial development (Additional file 6: Table S5). On C2cp gene sets (canonical pathway in MSigDB), the results for the positively ranked genes or functions enriched with high SCORE-AN were also obviously enriched for cancer-related functionalities (Additional file 7: Table S6) but no gene sets with statistical significance were observed for genes with low SCORE-AN (Additional file 8: Table S7).

Mutational hotspots and accumulation order

We next investigated somatic mutations occurring on known mutation hotspots and their temporal mutation order. Chang et al. previously defined 470 mutational hotspots in 275 genes and we investigated all of the pairs of hotspot mutations to detect the temporal sequence of mutations on known hotspots [26]. However, the number of mutation pairs harboring the hotspot mutations was too small for our GLRT-based statistical models (number of cases ≤ 5).

It has been previously reported that APC mutations may initiate the process of colon cancer development as one of the earliest genomic aberrations [27], but we did not obtain clear results for the early occurrence of APC mutations in the gene-level experiments shown in the previous section. We divided the APC mutations into hotspot mutations and non-hotspot mutations and then investigated the CCF distribution. The APC non-hotspot mutations showed relatively low CCF values compared with the APC hotspot mutations (Additional file 9: Figure S2(a)). When we further examined four cases harboring both APC:Q1387 hotspot mutations and TP53 mutations, the APC:Q1387 hotspot mutations had higher CCF values compared with TP53 mutation, and it is reasonable to assume that the APC:Q1387 mutations would be an ancestor of the TP53 mutations in these cases (Additional file 9: Figure S2(b)).

Discussion

The identification of known and novel cancer drivers with moderate-to-high population-level frequency of somatic mutations has been one of the major goals in cancer genome analyses [28, 29]. However, the temporal sequence of somatic mutations, i.e., which somatic mutations occurred earlier in the evolution of cancer genomes than others, is still largely unknown. Early- and late-occurring somatic mutations have different biological and clinical implications-the early addicted somatic mutations may serve as appropriate targets for therapeutic intervention while late-occurring cancer drivers have been associated with therapeutic resistance or disease progression. The distinction of such early and late genomic events, especially for somatic mutations, has been previously investigated using VAF or CCF. However, VAF- or CCF-based discrimination of early/clonal and late/subclonal mutations is limited to an individual genome and may miss information inferring the temporal relationship between mutations. To solve this problem, we built a GLRT-based statistical framework to determine the temporal sequence of somatic mutations from mutation profiles of multiple individuals (population-level genomics data). This population-scale analysis may capture the temporal sequence of somatic mutations and identify the temporal sequence or hierarchy of somatic mutations of a given tumor type. Similar approaches have been previously proposed in which genomic data of multiple tumors (i.e., binary calls of chromosomal amplifications or deletions) at their fully transformed stages may be used to deduce the temporal sequence of genomic events (RESIC [4]); however, we extended this idea by exploiting the distinction of clonal versus subclonal mutations based on CCF estimates of individual mutations. We applied our method to publicly available mutation profiles of eight major human tumor types. For this, we carried out pairwise comparisons between somatic mutations based on a statistical test to infer the temporal order among them. Thus, it would be impossible to detect the effects of multiple factors on mutation acquisition. Although technical innovations have been proposed to solve this issue, e.g. single cell sequencing from a bulk tumor genome or longitudinal biopsies, these methods are largely limited in terms of cost or patient safety issues. Given that sequencing-based large-scale mutation profiles are currently available to the research community, such as those from the TCGA consortium used in our study, our method can be further applied to other datasets or tumor types. In addition, we assumed that Ci and Cj were under i.i.d. condition, and applied GLRT. Biologically, this assumption of independency between two mutations may not be valid given the crosstalk or interplay between genomic alterations in cancer cells. Other statistics for inference of mutational orders, such as an order statistic, can be considered as an alternative to GLRT.

Among the tumor types examined, we identified TP53 mutations as a recurrently observed hub connected with other cancer-related genes, consistent with its prevalent and known roles in tumorigenesis across multiple cancer types [30]. Among the mutation pairs involving TP53, we observed the mutation pair of KRASTP53 as a well-recognized mutation sequence in the stepwise colorectal carcinogenesis [2]. In addition, we recurrently observed the mutation pairs of TP53LRP1B and TP53KMT2C across multiple tumor types. Inactivation of LRP1B increased the invasive potential in an in vitro setting, implicating a role of LRP1B mutations in the later stages of carcinogenesis [31]. Whether the mutations in epigenetic modifiers are early or late events drivers is a subject of debate, with lines of evidence supporting early events for TET2 mutations [32] or late events for SETD2 mutations [33]. Our results suggest that KMT2C mutations are descendant genomic events relative to TP53 mutations in LUAD and HNSC, but further experimental validation in terms of multiregion sequencing or other method is required. Moreover, as we expected, non-CGC genes were commonly observed as descendants of a CGC gene in multiple tumor types (Fig. 3 and Additional File 10: Table S8). For example, USH2A mutation was frequently observed in several tumor types as shown in Fig. 1a, but it was a late event occurring after TP53 or KRAS mutation.

In the case of COADREAD, the mutation pair of KRASAPC was observed even though it is generally recognized that APC mutations occur early, before KRAS and TP53 mutations. One limitation of our methodology is that only SNVs available for CCF can be used as input of the algorithm. In the case of APC, chromosomal deletions or frameshifting indels may be also responsible for APC inactivation and our methods may not adequately evaluate the genetic hierarchy of tumor suppressors such as APC. When we limit the APC mutations to those on a known mutation hotspot (APC:Q1387) accompanying TP53 mutations (four COADREAD cases), the CCF values of APC mutations were higher than those of TP53 mutations suggesting that APC mutation may have occurred earlier than TP53 mutation in those cases.

The population scale inference of mutational orders assumes that the mutation processes are uniform across the cases, or at least for the majority of cases. This assumption, and the related results, should be interpreted with caution since the sequence of mutation accumulation can be specific in individual cancer genomes and distinctive to patient subgroups, according to their tumor subtype or other clinical features. By collecting many more samples with information, the specific accumulation patterns (e.g., candidate sets of mutation orders) may be further investigated and might help elucidate individual features such as the treatment response.

Conclusions

In spite of several limitations, our results inferred a genetic hierarchy between somatic mutations as part of the cancer genome evolution. We found some ordered pairs of genes within cancer-related genes in each tumor and this information will provide mechanistic insights into the tumor initiation process. We also demonstrated that the scores of mutation co-occurrence (SCORE-CO) or ancestor/descendant ratio (SCORE-AN) may help identify or prioritize new candidates of driver mutations in each tumor. Furthermore, the study on mutation hotspot information may be more robust in that the hotspot mutations represent functionally relevant cancer drivers as shown in the example of APC mutations in COADREAD. In summary, our proposed statistical framework can be used to infer the temporal sequence of somatic mutations in population-scale cancer genomics data, providing information regarding the timing of mutation occurrence in given tumor types.

Declarations

Acknowledgements

The authors wish to acknowledge the financial support of the Catholic Medical Center Research Foundation made in the program year of 2015.

Funding

The publication cost of this article was funded by the Korea Health Technology R&D Project via the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant no. HI15C3224) and by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, ICT, and Future Planning, Republic of Korea (grant no. NRF-2015R1C1A1A01053824) in part.

Availability of data and materials

The datasets analysed during the current study are available in the TCGA repository. Also, the source code used in the experiments is available at https://github.com/jkrhee/MutationTemporalSequence.

About this supplement

This article has been published as part of BMC Medical Genomics Volume 11 Supplement 2, 2018: Proceedings of the 28th International Conference on Genome Informatics: medical genomics. The full contents of the supplement are available online at https://bmcmedgenomics.biomedcentral.com/articles/supplements/volume-11-supplement-2.

Authors’ contributions

JKR and TMK conceived the study, analyzed the experimental results, and wrote the manuscript. JKR collected the data, implemented the tool and performed the computational experiments. Both authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Cancer Research Institute, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea
(2)
Department of Medical Informatics, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea

References

  1. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013; 153(1):17–37.View ArticlePubMedGoogle Scholar
  2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759–67.View ArticlePubMedGoogle Scholar
  3. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010; 11(10):685–96.View ArticlePubMedGoogle Scholar
  4. Attolini CS-O, Cheng YK, Beroukhim R, Getz G, Abdel-Wahab O, Levine RL, Mellinghoff IK, Michor F. A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci. 2010; 107(41):17604–9.View ArticlePubMedGoogle Scholar
  5. Hu W, Li X, Wang T, Zheng S. Association mining of mutated cancer genes in different clinical stages across 11 cancer types. Oncotarget. 2016; 7(42):68270.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Tomasetti C, Vogelstein B, Parmigiani G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci. 2013; 110(6):1999–2004.View ArticlePubMedGoogle Scholar
  7. Foo J, Liu LL, Leder K, Riester M, Iwasa Y, Lengauer C, Michor F. An evolutionary approach for identifying driver mutations in colorectal cancer. PLoS Comput Biol. 2015; 11(9):1004350.View ArticleGoogle Scholar
  8. McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med. 2015; 7(283):283–5428354.View ArticleGoogle Scholar
  9. Jiang Y, Qiu Y, Minn AJ, Zhang NR. Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing. Proc Natl Acad Sci. 2016; 113(37):5528–37.View ArticleGoogle Scholar
  10. Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015; 372(7):601–12.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, Laird PW, Onofrio RC, Winckler W, Weir BA, et al. Absolute quantification of somatic dna alterations in human cancer. Nat Biotechnol. 2012; 30(5):413–21.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013; 152(4):714–26.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR. A census of human cancer genes. Nat Rev Cancer. 2004; 4(3):177–83.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, Yenamandra A, Locke K, Yuan J-l, Bonine-Summers AR, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell. 2010; 18(5):436–47.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011; 2(4):466–74.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Petitjean A, Achatz M, Borresen-Dale A, Hainaut P, Olivier M. Tp53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007; 26(15):2157–65.View ArticlePubMedGoogle Scholar
  17. Wang Y, Zhang Z, Lubet R, You M. A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice. Oncogene. 2006; 25(8):1277–80.View ArticlePubMedGoogle Scholar
  18. Anoosha P, Huang LT, Sakthivel R, Karunagaran D, Gromiha MM. Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer. Mutat Res Fundam Mol Mech Mutagen. 2015; 780:24–34.View ArticleGoogle Scholar
  19. Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015; 4(1):36.PubMedPubMed CentralGoogle Scholar
  20. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. Egfr-mutated lung cancer: a paradigm of molecular oncology. Oncotarget. 2010; 1(7):497.PubMedPubMed CentralGoogle Scholar
  21. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in notch1. Science. 2011; 333(6046):1154–7.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of k-ras, p53, and apc mutations in colorectal carcinoma. Gut. 2005; 54(9):1283–6.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ, Wolf CR. Mutations in apc, kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci. 2002; 99(14):9433–8.View ArticlePubMedGoogle Scholar
  24. Supek F, Lehner B. Differential dna mismatch repair underlies mutation rate variation across the human genome. Nature. 2015; 521(7550):81–4.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005; 102(43):15545–50.View ArticlePubMedGoogle Scholar
  26. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao J, Socci ND, Solit DB, Olshen AB, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016; 34(2):155–63.View ArticlePubMedGoogle Scholar
  27. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996; 87(2):159–70.View ArticlePubMedGoogle Scholar
  28. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214–8.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC, Mooney TB, Callaway MB, Dooling D, Mardis ER, et al. Music: identifying mutational significance in cancer genomes. Genome Res. 2012; 22(8):1589–98.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Olivier M, Hollstein M, Hainaut P. Tp53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010; 2(1):001008.View ArticleGoogle Scholar
  31. Prazeres H, Torres J, Rodrigues F, Pinto M, Pastoriza M, Gomes D, Cameselle-Teijeiro J, Vidal A, Martins T, Sobrinho-Simoes M, et al. Chromosomal, epigenetic and microrna-mediated inactivation of lrp1b, a modulator of the extracellular environment of thyroid cancer cells. Oncogene. 2011; 30(11):1302–17.View ArticlePubMedGoogle Scholar
  32. Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, Adès L, Fenaux P, Platzbecker U, Gagey O, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013; 121(12):2186–98.View ArticlePubMedGoogle Scholar
  33. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883–92.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

Advertisement